Skip to content

Impact of effect of Ayurvedic treatment on novel Corona virus disease

Impact of Indian traditional Ayurvedic treatment regime for nCoV-2 (COVID-19)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025273
Enrollment
120
Registered
2020-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J969- Respiratory failure, unspecified

Interventions

Intervention1: Ayurvedic Therapy: Tablet Pure Ashwagandha 500mg BD, Oral, After Breakfast / Dinner Tablet Pure Giloy Extract 1000 mg BD, Oral, after Breakfast / Dinner Tablet Pure Tulsi Extract 500

Sponsors

Patanjali Research Institute
Lead Sponsor
National Institute of Medical Sciences Jaipur
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Asymptomatic patients Mildly symptomatic patients Moderately symptomatic patients Age 15-80 years of age Patients able to give Informed consent and follow instructions Agree to follow at 14 days and 30 days after testing positive for COVID-19

Exclusion criteria

Exclusion criteria: Severely symptomatic patients (SaO2 Acute Respiratory Distress Syndrome (ARDS) Life expectancy less than 1 year due to other co-morbid conditions

Design outcomes

Primary

MeasureTime frame
Virological Clearance as measured by RT PCR of nasopharyngeal swabTimepoint: Baseline, 3 Days, 7 Days, 14 Days

Secondary

MeasureTime frame
Conversion from Symptomatic to Asymptomatic patient Reduction in C-reactive protein, ESR & IL-6 Improvement in heamatological parameters eg Total Leucocyte count Safety analysisTimepoint: Baseline, 3 Days, 7 Days, 14 Days

Countries

India

Contacts

Public ContactDr Abhishek Sharma

National Institute of Medical Sciences

dr.abhisheksharma1987@gmail.com9828816135

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 24, 2026